Oslo, Norway, October 21, 2026
SonoClear AS has announced that the U.S. Food and Drug Administration (FDA) has accepted its 510(k) submission for substantive review of the SonoClear System, an innovative acoustic coupling fluid designed to improve ultrasound imaging during brain tumor surgery. The regulatory milestone brings the Norwegian medical technology company’s investigational product closer to potential commercialization in the United States. The system is designed to reduce imaging artifacts that can obscure the surgical cavity during tumor removal, helping neurosurgeons visualize important anatomical details more clearly. Previously granted FDA Breakthrough Device Designation, the SonoClear System is being developed to address a technical limitation in intraoperative ultrasound imaging. However, acceptance of the submission does not mean the device has received FDA clearance, and it is not currently authorized for sale or distribution.
SonoClear System Targets Ultrasound Imaging Challenges
The SonoClear System is a sterile, biocompatible and bio-excretable acoustic coupling fluid developed specifically for use during ultrasound-guided brain tumor resections. During neurosurgical procedures, intraoperative ultrasound allows surgeons to examine the surgical cavity in real time and assess whether tumor tissue may remain after resection. However, conventional irrigation fluids, such as saline, can produce bright acoustic artifacts and visual noise that interfere with image interpretation. SonoClear is engineered to match the acoustic properties of brain tissue, with the aim of reducing these artifacts and improving visualization within the resection cavity. By creating clearer ultrasound images, the system is intended to support surgical decision-making when clinicians assess tumor boundaries and possible residual disease. This capability may be particularly valuable during glioma surgery, where distinguishing tumor tissue from surrounding healthy brain structures is critical. More accurate visualization could potentially help surgeons make better-informed decisions about the extent of tumor removal while balancing the need to preserve healthy tissue and neurological function. Although the technology is designed to improve image quality, better imaging does not automatically establish improved surgical outcomes. Further clinical evidence will be needed to determine whether its use leads to measurable benefits for patients.
FDA 510(k) Review Follows Pivotal Clinical Study
The FDA’s acceptance of the 510(k) submission marks an important regulatory step for SonoClear AS. The company previously received Breakthrough Device Designation in July 2025, recognizing the potential of the technology to address an important clinical need. This designation supports the development and review process but does not constitute marketing authorization. The regulatory submission follows a pivotal clinical study involving 44 patients. Data from the study were presented at the 2026 annual congress of the European Association of Neurosurgical Societies. According to the company, the SonoClear System met the study’s primary and secondary safety endpoints and demonstrated an indication of improved overall ultrasound image quality compared with standard irrigation. The study findings provide clinical evidence supporting continued evaluation of the technology. Nevertheless, the reported image-quality observations should not be interpreted as definitive proof that the system improves long-term patient outcomes, reduces tumor recurrence or increases survival. The FDA’s substantive review will determine whether the submitted evidence meets the applicable requirements for 510(k) clearance. Until the agency reaches a decision, the SonoClear System remains an investigational product and cannot be marketed in the United States.
Advertisement
SonoClear Advances Toward U.S. Commercialization
For SonoClear AS, the regulatory milestone represents progress toward its goal of introducing the system to U.S. neurosurgical teams. The company was established to develop technologies that improve diagnostic accuracy in ultrasound-guided interventions, and the SonoClear System represents its approach to addressing image-quality limitations during brain surgery. If cleared, the technology could provide surgeons with an additional tool for intraoperative imaging without replacing the ultrasound systems already used in operating rooms. Its intended role is to improve the acoustic coupling environment and support clearer visualization during tumor resection. The company’s next steps will depend on the outcome of the FDA review and any additional requirements identified by regulators. Commercial adoption would also depend on clinical utility, integration into surgical workflows and acceptance by healthcare providers. The acceptance of the 510(k) submission is a regulatory milestone, not an FDA clearance announcement. Further review will establish whether the available evidence supports marketing authorization. If successful, the SonoClear System could offer a new approach to improving intraoperative ultrasound visualization and supporting surgical decision-making in brain tumor procedures.
Source: SonoClear AS press release
